Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $1.31 in the prior trading day, Coherus Oncology Inc (NASDAQ: CHRS) closed at $1.33, up 1.53%. In other words, the price has increased by $1.53 from its previous closing price. On the day, 1.02 million shares were traded. CHRS stock price reached its highest trading level at $1.34 during the session, while it also had its lowest trading level at $1.29.
Ratios:
Our goal is to gain a better understanding of CHRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.44. In the meantime, Its Debt-to-Equity ratio is 0.45 whereas as Long-Term Debt/Eq ratio is at 0.44.
On August 16, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $4 to $1.50. On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.Robert W. Baird initiated its Outperform rating on November 17, 2023, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 154581920 and an Enterprise Value of -42025724. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.08 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at -0.154 whereas that against EBITDA is 0.501.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.90, which has changed by 0.023076892 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 30.41%, while the 200-Day Moving Average is calculated to be 24.12%.
Shares Statistics:
The stock has traded on average 1.33M shares per day over the past 3-months and 1157590 shares per day over the last 10 days, according to various share statistics. A total of 116.22M shares are outstanding, with a floating share count of 105.68M. Insiders hold about 9.07% of the company’s shares, while institutions hold 46.81% stake in the company. Shares short for CHRS as of 1756425600 were 31928030 with a Short Ratio of 23.95, compared to 1753920000 on 32335829. Therefore, it implies a Short% of Shares Outstanding of 31928030 and a Short% of Float of 28.57.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.12 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.31 and -$1.31 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$0.79, with 2.0 analysts recommending between -$0.44 and -$1.13.
Revenue Estimates
5 analysts predict $13.41M in revenue for the current quarter. It ranges from a high estimate of $15M to a low estimate of $12M. As of the current estimate, Coherus Oncology Inc’s year-ago sales were $70.77MFor the next quarter, 5 analysts are estimating revenue of $15.76M. There is a high estimate of $17.57M for the next quarter, whereas the lowest estimate is $12M.
A total of 4 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $49.2M, while the lowest revenue estimate was $42.02M, resulting in an average revenue estimate of $46.27M. In the same quarter a year ago, actual revenue was $266.96MBased on 5 analysts’ estimates, the company’s revenue will be $96.91M in the next fiscal year. The high estimate is $161.64M and the low estimate is $61.94M.
